Lexicon Pharmaceuticals, INC. (LXRX) — 8-K Filings

8-K Filings (23)

• 8-K Filing — Nov 10, 2025
• Lexicon Pharmaceuticals Files 8-K Report — Nov 6, 2025 Risk: low
  On November 6, 2025, Lexicon Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," in
• Lexicon Pharmaceuticals Files 8-K on Financials — Aug 6, 2025 Risk: low
  Lexicon Pharmaceuticals, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition. The filing includes financial stat
• Lexicon Sells Inhaled Program for $100M — Jul 28, 2025 Risk: medium
  Lexicon Pharmaceuticals, Inc. announced on July 23, 2025, that it has entered into a definitive agreement to sell its Inhaled Inhaled program, including LX2761,
• Lexicon Pharmaceuticals Files 8-K — Jul 3, 2025 Risk: low
  Lexicon Pharmaceuticals, Inc. filed an 8-K on July 3, 2025, reporting an event under 'Other Events'. The filing does not contain specific details about the even
• Lexicon Pharmaceuticals Files 8-K on Material Agreement — Jun 3, 2025 Risk: medium
  On June 2, 2025, Lexicon Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes information regarding mat
• Lexicon Pharmaceuticals Files 8-K on Financials — May 13, 2025 Risk: low
  Lexicon Pharmaceuticals, Inc. filed an 8-K on May 13, 2025, reporting on its results of operations and financial condition, as well as filing financial statemen
• Lexicon Pharmaceuticals Enters Material Definitive Agreement — Mar 28, 2025 Risk: medium
  On March 27, 2025, Lexicon Pharmaceuticals, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits relate
• Lexicon Pharmaceuticals Files 8-K on Financials — Mar 6, 2025 Risk: low
  Lexicon Pharmaceuticals, Inc. filed an 8-K on March 6, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Lexicon Pharmaceuticals Faces Listing Rule Issues — Jan 7, 2025 Risk: high
  Lexicon Pharmaceuticals, Inc. filed an 8-K on January 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a
• Lexicon Pharma Appoints New CMO, Adds Director — Jan 2, 2025 Risk: medium
  Lexicon Pharmaceuticals, Inc. announced on January 2, 2025, the appointment of Dr. Tamara Joseph as Chief Medical Officer and the election of Ms. Michelle L. Gr
• Lexicon Pharma Reports Exit/Disposal Costs — Nov 22, 2024 Risk: medium
  Lexicon Pharmaceuticals, Inc. filed an 8-K on November 22, 2024, to report on costs associated with exit or disposal activities. The filing does not specify the
• Lexicon Pharmaceuticals Appoints New Chief Medical Officer — Nov 20, 2024 Risk: medium
  Lexicon Pharmaceuticals, Inc. announced on November 19, 2024, the appointment of Dr. Tamara A. Z. Joseph as Chief Medical Officer, effective November 20, 2024.
• Lexicon Pharmaceuticals Files 8-K on Financials — Nov 12, 2024 Risk: low
  Lexicon Pharmaceuticals, Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition, as well as filing financial sta
• Lexicon Pharmaceuticals Enters Material Definitive Agreement — Oct 16, 2024 Risk: medium
  On October 16, 2024, Lexicon Pharmaceuticals, Inc. entered into a material definitive agreement. The filing does not disclose the specific details of this agree
• Lexicon Pharma Appoints New Chief Medical Officer — Sep 16, 2024 Risk: medium
  Lexicon Pharmaceuticals, Inc. announced on September 13, 2024, the appointment of Dr. Tamara A. P. von Koch as Chief Medical Officer, effective September 16, 20
• Lexicon Pharmaceuticals Files 8-K on Financials — Aug 1, 2024 Risk: low
  Lexicon Pharmaceuticals, Inc. filed an 8-K on August 1, 2024, reporting on its results of operations and financial condition. The filing includes financial stat
• Lexicon Pharma Appoints New Chief Medical Officer — Jul 8, 2024 Risk: medium
  Lexicon Pharmaceuticals, Inc. announced on July 3, 2024, the appointment of Dr. Tamara A. Z. Joseph as Chief Medical Officer, effective July 8, 2024. Dr. Joseph
• Lexicon Pharmaceuticals Enters Material Definitive Agreement — Jul 1, 2024 Risk: medium
  On June 28, 2024, Lexicon Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The filing does not disclose specific details of the agreement or
• Lexicon Pharmaceuticals Files 8-K with Equity, Bylaw, and Shareholder Votes — May 10, 2024 Risk: medium
  Lexicon Pharmaceuticals, Inc. filed an 8-K on May 10, 2024, reporting on several key events. These include unregistered sales of equity securities, amendments t
• Lexicon Pharmaceuticals Announces CMO Retirement and Appointment — Apr 29, 2024 Risk: medium
  Lexicon Pharmaceuticals, Inc. announced on April 24, 2024, the retirement of its Chief Medical Officer, Dr. Jeffrey L. Cleary, effective June 30, 2024. Dr. Clea
• Lexicon Pharmaceuticals Files 8-K on Corporate Changes — Mar 12, 2024 Risk: low
  On March 12, 2024, Lexicon Pharmaceuticals, Inc. filed an 8-K report detailing material modifications to the rights of security holders and amendments to its ar
• Lexicon Pharmaceuticals Announces Material Agreement & Financial Updates — Mar 11, 2024 Risk: medium
  Lexicon Pharmaceuticals, Inc. announced on March 6, 2024, that it entered into a material definitive agreement. The company also reported its results of operati

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX